In a phase I-II clinical study (NCT02079740), navitoclax was administered in combination with the MEK inhibitor trametinib for the treatment of solid tumors harboring KRAS and NRAS mutations; however, no partial responses (PR) were observed among CRC patients (121). The gene discussed is KRAS; the disease is colorectal carcinoma.